市建局橡樹街/埃華街項目收最少21份意向
市區重建局大角咀橡樹街/埃華街發展項目今日(10日)截收合作發展意向書,現場所見最少收21份意向書,包括萊蒙國際(03688.HK)、其士國際(00025.HK)及華懋集團、碧桂園(02007.HK)、旭暉(00884.HK)、英皇國際(00163.HK)、德祥地產(00199.HK)、南豐、宏安地產(01243.HK)、爪哇(00251.HK)、遠洋集團(03377.HK)、宏基資本(02288.HK)等。
宏基資本投資分析師莫京燐指,公司之前亦有做過住宅項目,認為附近很多重建進行中,發展潛力巨大。項目於2018年3月展開,地盤面積為619平方米,項目完成後預計可提供上限為5,571平方米的總樓面面積。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.